These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32974635)

  • 41. Assessing, updating and utilising primary care smoking records for lung cancer screening.
    McCutchan G; Engela-Volker J; Anyanwu P; Brain K; Abel N; Eccles S
    BMC Pulm Med; 2023 Nov; 23(1):445. PubMed ID: 37974137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of an Electronic Health Record-Based Algorithm for Predicting Lung Cancer Screening Eligibility in the Population-Based Research to Optimize the Screening Process Lung Research Consortium.
    Burnett-Hartman AN; Powers JD; Hixon BP; Carroll NM; Frankland TB; Honda SA; Saia C; Rendle KA; Greenlee RT; Neslund-Dudas C; Zheng Y; Vachani A; Ritzwoller DP
    JCO Clin Cancer Inform; 2023 Sep; 7():e2300063. PubMed ID: 37910824
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of discrimination performance of 11 lung cancer risk models for predicting lung cancer in a prospective cohort of screening-age adults from Germany followed over 17 years.
    Bhardwaj M; Schöttker B; Holleczek B; Brenner H
    Lung Cancer; 2022 Dec; 174():83-90. PubMed ID: 36356492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.
    Ten Haaf K; Bastani M; Cao P; Jeon J; Toumazis I; Han SS; Plevritis SK; Blom EF; Kong CY; Tammemägi MC; Feuer EJ; Meza R; de Koning HJ
    J Natl Cancer Inst; 2020 May; 112(5):466-479. PubMed ID: 31566216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer.
    Choi E; Sanyal N; Ding VY; Gardner RM; Aredo JV; Lee J; Wu JT; Hickey TP; Barrett B; Riley TL; Wilkens LR; Leung AN; Le Marchand L; Tammemägi MC; Hung RJ; Amos CI; Freedman ND; Cheng I; Wakelee HA; Han SS
    J Natl Cancer Inst; 2022 Jan; 114(1):87-96. PubMed ID: 34255071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of risk prediction models to lung cancer screening: a review.
    Tammemägi MC
    J Thorac Imaging; 2015 Mar; 30(2):88-100. PubMed ID: 25692785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
    Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
    Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?
    Pinsky PF; Berg CD
    J Med Screen; 2012 Sep; 19(3):154-6. PubMed ID: 23060474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
    Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
    Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
    J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    Pu CY; Lusk CM; Neslund-Dudas C; Gadgeel S; Soubani AO; Schwartz AG
    JAMA Oncol; 2022 Mar; 8(3):374-382. PubMed ID: 35024781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort.
    Singh S; Pavesi F; Steiling K; Asokan S; Espinosa C; Cabral HJ; Burks EJ; Meister A; Akpoviroro O; Buck A; Drozdowicz K; Litle VR; Suzuki K
    Clin Lung Cancer; 2022 Mar; 23(2):e165-e170. PubMed ID: 34393063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimating eligibility for lung cancer screening in an Australian cohort, including the effect of spirometry.
    Manners D; Hui J; Hunter M; James A; Knuiman MW; McWilliams A; Mulrennan S; Musk AW; Brims FJ
    Med J Aust; 2016 Jun; 204(11):406. PubMed ID: 27318396
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance.
    Carroll NM; Burnett-Hartman AN; Joyce CA; Kinnard W; Harker EJ; Hall V; Steiner JS; Blum-Barnett E; Ritzwoller DP
    J Gen Intern Med; 2020 Apr; 35(4):1143-1152. PubMed ID: 31974902
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adherence to general medical checkup and cancer screening guidelines according to self-reported smoking status: Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012.
    Kim EY; Shim YS; Kim YS; Lee SP; Ko KD; Choi WJ
    PLoS One; 2019; 14(10):e0224224. PubMed ID: 31639166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk-Based lung cancer screening: A systematic review.
    Toumazis I; Bastani M; Han SS; Plevritis SK
    Lung Cancer; 2020 Sep; 147():154-186. PubMed ID: 32721652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    Fahrmann JF; Marsh T; Irajizad E; Patel N; Murage E; Vykoukal J; Dennison JB; Do KA; Ostrin E; Spitz MR; Lam S; Shete S; Meza R; Tammemägi MC; Feng Z; Hanash SM
    J Clin Oncol; 2022 Mar; 40(8):876-883. PubMed ID: 34995129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
    Bartlett EC; Kemp SV; Ridge CA; Desai SR; Mirsadraee S; Morjaria JB; Shah PL; Popat S; Nicholson AG; Rice AJ; Jordan S; Begum S; Mani A; Derbyshire J; Morris K; Chen M; Peacock C; Addis J; Martins M; Kaye SB; Padley SPG; Devaraj A;
    Lung Cancer; 2020 Oct; 148():12-19. PubMed ID: 32771715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors Associated with a Positive Baseline Screening Exam Result in the National Lung Screening Trial.
    Balekian AA; Tanner NT; Fisher JM; Silvestri GA; Gould MK
    Ann Am Thorac Soc; 2016 Sep; 13(9):1568-74. PubMed ID: 27387658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.